Role of Dopamine Receptors in Primary Focal Dystonias

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified August 2011 by Washington University School of Medicine
Sponsor:
Collaborator:
Information provided by:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT01373840
First received: June 10, 2011
Last updated: August 2, 2011
Last verified: August 2011

June 10, 2011
August 2, 2011
September 2011
April 2016   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01373840 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Role of Dopamine Receptors in Primary Focal Dystonias
Role of Dopamine Receptors in Primary Focal Dystonias

Dystonia is a disabling movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures that may afflict 250,000 people in the U.S. While the pathophysiology of dystonia remains uncertain the treatment is rather rudimentary. A better understanding of neural mechanisms of dystonias is not only an invaluable prerequisite for developing better treatment options but also a step toward better understanding of the complex network of basal ganglia. In this study I will investigate if there is any difference between the dopamine receptors and dopamine in people with dystonia and healthy subjects.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Any healthy control or patient with primary focal dystonia or arm or face.

  • Healthy
  • Focal Dystonias
Not Provided
  • healthy controls
  • patients with focal dystonias
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
40
Not Provided
April 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age >20
  • Male or Female
  • Any race or ethnicity
  • Primary focal dystonia (arm or cranial)
  • Ability to give informed consent

Exclusion criteria:

  • Family history of dystonia
  • Pregnancy (confirmed with negative urine pregnancy test in women of child bearing potential), breastfeeding
  • Exposure to radiation therapy
  • Any MRI contraindications such as foreign metallic implants, pacemaker, and aneurysm clip etc.
  • History of cardiac disease, uncontrolled hypertension, abnormal EKG during screening phase
  • History of exposure to any drugs affecting dopaminergic systems within the last 6 months (e.g. dopamine receptor blocking agents, cocaine, amphetamine, tetrabenazine, reserpine, L-dopa, dopamine agonists, as they might affect the dopamine receptor binding or endogenous dopamine).
  • Active depression (Beck Depression Inventory_II >14)
  • Cognitive impairment (Mini-Mental State Score <27)
  • CNS active medications such as gabapentin or narcotics, muscle relaxants which might be given for pain in the 3 days prior to study
  • History of stroke, seizure, cerebral palsy, generalized dystonia, parkinsonism, inability to hold head still during the scanning time.
Both
21 Years and older
Yes
Contact: Pratt Stacey 314-747-5916 pratts@npg.wustl.edu
United States
 
NCT01373840
201102481
No
Morvarid Karimi, MD, Washington University
Washington University School of Medicine
National Institute of Neurological Disorders and Stroke (NINDS)
Principal Investigator: Morvarid Karimi, MD Washington University Early Recognition Center
Washington University School of Medicine
August 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP